The Trump administration has officially reclassified state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, the most significant federal cannabis policy change in more than 50 years.
What the Reclassification Actually Does
Acting Attorney General Todd Blanche signed the order, shifting licensed medical marijuana from Schedule I, reserved for drugs with no accepted medical use and high abuse potential, to Schedule III, which carries moderate to low potential for physical and psychological dependence.
The order does not legalize marijuana for medical or recreational use under federal law. But it meaningfully changes how the substance is regulated and studied.
It also gives licensed medical marijuana operators a significant tax break and eases some barriers to researching cannabis.
Who Is Affected and What Comes Next
The reclassification largely legitimizes medical marijuana programs in the 40 states that have adopted them. It sets up a registration pathway for state-licensed producers and distributors with the DEA.
Marijuana or marijuana-derived products not distributed through a state medical marijuana program will continue to be classified as Schedule I.
The administration also announced an expedited administrative hearing process aimed at rescheduling cannabis from Schedule I to Schedule III more broadly, with a hearing set to begin in late June.
Why This Matters for Addiction Treatment
The rescheduling has direct implications for addiction treatment and mental health care. Schedule I status has long blocked rigorous clinical study of cannabis, including its potential role in managing pain, anxiety disorder, PTSD, and withdrawal symptoms that often appear in addiction treatment settings.
The change makes clear that cannabis researchers won’t face legal penalties for obtaining state-licensed marijuana for use in their work. That could accelerate studies into how cannabis interacts with co-occurring conditions, a major factor in rehab center treatment planning.
Reclassifying marijuana as a Schedule III drug places it in the same bracket as Tylenol with codeine, medically beneficial drugs with low abuse potential under federal guidelines.
Some critics remain cautious. Opponents have pointed out that legalization in many states has led to increasingly potent cannabis products, which they argue require more study rather than lighter federal oversight.
What This Means for Treatment Seekers
If you or a loved one is researching addiction treatment options, this policy shift is worth understanding. Cannabis use disorder is among the most commonly treated conditions in outpatient rehab, and co-occurring cannabis and opioid use is frequently addressed in medication-assisted treatment (MAT) programs.
As federal research barriers ease, treatment providers may gain access to better clinical data on cannabis-related care, which could improve how rehab centers screen, assess, and treat patients.
If you’re currently in treatment or considering it, talk to your provider about how cannabis use, including medical marijuana, factors into your individualized care plan.
Exploring Treatment Options
The federal reclassification of marijuana adds complexity for both treatment seekers and providers. If you or someone you care about is dealing with cannabis use disorder, polysubstance use, or a co-occurring mental health condition, finding a qualified rehab center that offers individualized assessments is essential.
Rehab.com’s directory includes thousands of certified rehab centers nationwide. Call
800-985-8516
( 
Sponsored Helpline )
to speak with a treatment advisor.
